Key result
Restrictive annuloplasty improves NYHA class and LV function in chronic MR with ~3% 30-day mortality.
Why the study?
The early and late outcomes of restrictive mitral valve annuloplasty in patients with chronic mitral regurgitation and advanced ischemic or dilated cardiomyopathy were not well characterized.
Does restrictive mitral valve annuloplasty improve survival, symptoms, and LV function in patients with cardiomyopathy and chronic severe mitral regurgitation?
Population
121 patients with advanced ischemic (n=102) or dilated cardiomyopathy (n=19) and chronic MR grade 3-4
Comparison
Restrictive prosthetic ring annuloplasty with or without concomitant CABG
Design
Cohort study
Follow-up
30 +/- 12 months
Authors
Loading...
May improve symptoms and LV function in cardiomyopathy with MR; hypothesis-generating for remodeling and survival, pending RCTs.
Cohort (n=121)
Does restrictive mitral valve annuloplasty improve survival, symptoms, and LV function in patients with cardiomyopathy and chronic severe mitral regurgitation?
p-value: p=<0.0005
Restrictive mitral valve annuloplasty safely corrects chronic MR and improves contractility in cardiomyopathy patients, though continuous reverse remodeling is primarily seen in ischemic patients undergoing concomitant CABG.
Geidel et al. (2008) conducted a cohort in chronic mitral regurgitation and advanced ischemic or dilated cardiomyopathy (n=121). Restrictive mitral valve annuloplasty was evaluated on survival, residual MR, NYHA class and left ventricular function (p=<0.0005). Restrictive mitral valve annuloplasty in patients with cardiomyopathy and chronic MR yielded 3.3% 30-day mortality and significantly improved NYHA class and LV function (P<0.0005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: